Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Completed Trials

Bladder

HCRN GU15-215

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer Read More

BTCRC-GU16-051

Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients Read More

GU12-160

The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160 Read More

GU12-157

A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157 Read More

GU10-148

Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148 Read More

GU10-147

Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147. Read More

GU07-123

Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder Read More

GU07-122

A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder Read More

GU04-75

A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75 Read More

GU00-13

A Phase II Study of ALIMTA in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Read More

GU98-2

Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study Read More

Breast

BRE09-146

PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146 Read More

BRE07-126

A Phase II Study of Lonafarnib in Patients with Locally advanced and Metastatic Breast Cancer: Hoosier Oncology Group: BRE07-126 Read More

BRE06-120

A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team Read More

BRE06-109

A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group Study BRE06-109 Read More

BRE05-97

A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen Read More

BRE04-80

A Phase I/II Study of PTK787 in Combination with Trastuzumab in Patients with Newly Diagnosed HER-2 Overexpressing Locally Recurrent or Metastatic Breast Cancer Read More

BRE03-61

A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients with Previously Treated HER-2 Positive Metastatic Breast Cancer Read More

BRE03-60

A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60 Read More

BRE02-43

A Pilot Trial Incorporating ZD1839 (IRESSA®) into Adjuvant Therapy for Breast Cancer

BRE00-10

Phase I/II Trial of Chronic Low Dose Epirubicin and SU5416 in Patients with Previously Untreated Metastatic Breast Cancer

BRE99-1

Phase II Trial of Gemcitabine, Paclitaxel and Trastuzumab in Metastatic Breast Cancer: a Hoosier Oncology Group Trial Read More

BRE98-1

Combined anti-microtubule therapy: A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer, Hoosier Oncology Group BRE98-1 Read More

BRE96-1

Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer Read More

BRE94-1

A Hoosier Oncology Group Phase II Study of Biweekly Cisplatin (C) and Paclitaxel (P) in the Treatment of Metastatic Breast Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial BRE94-1 Read More

BRE93-1

A Phase II Study of Oral Etoposide and Ifosfamide in the Treatment of Patients with Stage IV Breast Cancer

BRE92-1

A Phase III Study of Pre-Operative Chemotherapy, Cytoxan, Adria, 5-FU vs HD Adria, Cytoxan and G-CSF for Breast Cancer not Considered Candidates for Lumpectomy

BRE89-1

Carboplatin and WR-2721 as First-Line Chemotherapy for Metastatic Breast Cancer (MBC): A Hoosier Oncology Group Study BRE89-1 Read More

COE-05

A Retrospective Analysis of Proteomic, Genomic, and Pharmacogenetics in Patients Receiving Systemic Chemotherapy for Locally Advanced or Metastatic Breast Cancer Read More

COE-03

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

COE-02

Department of the Army, US Army Medical Research Acquisition Activity: Center of Excellence for Individualization of Therapy for Breast Cancer: Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

COE-01

Department of the Army, US Army Medical Research Acquisition Activity: Center of Excellence for Individualization of Therapy for Breast Cancer: Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

HOG-09

Phase II Study of Methotrexate, Vinblastine Adriamycin and Cisplatin (M-VAC) Combination Chemotherapy for Previously Untreated or Minimally Treated Advanced Adenocarcinoma of the Breast

HOG-07

A Prospective Randomized Controlled Study of Adjuvant Chemotherapy (Cytoxan, Methotrexate, 5-Fluorouracil, Vincristine, Prednisone) vs. No Therapy in Women with ER Negative and Axillary Lymph Node Negative Breast Cancer

HOG-04

Phase III Study of Megace vs Aminoglutethimide + Hydrocortisone in Previously Treated Hormonally Responsive Metastatic Breast Cancer

TBCRC12-142

ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer Read More

Cervical

GYN97-2

A Phase II Trial of Pre-operative Pelvic and Para-Aortic Radiotherapy and Radical Pelvic Surgery in Stages IIIB and IVA Carcinoma of the Cervix

Colorectal

GI14-191

A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy with Ginseng for Patients on Treatment with Regorafenib: HCRN GI14-191. Read More

HCRN GI14-186

A Multi-Center, Single Arm, Phase II study of Pembrolizumab (MK-3475) in Combination with Chemotherapy for Patients with Advanced Colorectal Cancer: HCRN GI14-186 Read More

GI05-102

Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102 Read More

GI00-2

A Phase II Trial of Irinotecan (CPT-11), 5-Fluorouracil (5-FU), Glutamine, Leucovorin and Celecoxib as First Line Therapy for Metastatic Colorectal Cancer –GI00-2 Read More

GI89-1

A Randomized Phase III Study of 5-Fluorouracil vs 5-Fluorouracil + Levamisole in Previously Untreated Metastatic Colon Cancer – GI89-1 Read More

HOG-05

Adjuvant Internal Radiotherapy to the Liver Using Colloidal 32p in Colon Cancer

HOG-01

A Randomized Phase III Study of 5-FU + Cisplatin in Previously Untreated Metastatic Adenocarcinoma of the Colon

Endometrial

BTCRC-GYN15-013

Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma Read More

GYN97-1

A Phase II Study of Intraperitoneal 32p and Vaginal Brachytherapy in the Treatment of Papillary Serous and Clear Cell Adenocarcinoma of the Endometrium Read More

Esophageal

GI06-112

A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer Read More

GI05-92

A Pilot Study With Cetuximab and Radiation Therapy for Patients With Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group Study (GI05-92) Read More

GI02-38

A Phase II Study of Capecitabine plus Docetaxel Combination in Patients with Esophageal/Gastric Cancer

GI00-16

A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation Therapy and Celecoxib for Resectable Esophageal Cancer – HOG GI 00-16 Read More

Germ Cell Tumors

GU14-206

A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients with incurable platinum refractory germ cell tumors. Read More

Head and Neck

HN96-1

A Phase II Trial of Doxil in Advanced or Recurrent Head and Neck Cancer

HN02-40

A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck Read More

HN94-1

A Phase II Trial of Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Cancer of the Head and Neck Read More

HN90-1

Phase II Trial of Interferon Alpha-2b plus Cisplatin and 5-FU in Recurrent or Metastatic Head and Neck Cancer Read More

Kidney

BTCRC-GU16-043

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043 Read More

HCRN GU15-223

Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223 Read More

BTCRC-GU14-003

Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003 Read More

GU09-145

Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors Read More

GU96-1

A Phase II Trial of Doxil in the Treatment of Advanced Renal Cell Cancer

GU94-1

A Phase II Trial of Levamisole in the Treatment of Advanced Renal Cell Cancer Read More

GU91-1

A Phase II Study of Altretamine (HEX) for the Treatment of Metastatic Renal Cell Cancer Read More

GU90-1

Phase II Study of Recombinant Interferon Alpha-2a in Metastatic Renal Cell Cancer Read More

GU88-1

Phase II Study of Vinblastine + Dipyridamole for Metastatic Renal Cell Carcinoma Read More

HOG-13

Phase II Study of High-Dose Cimetidine for Treatment of Metastatic Renal Cell Carcinoma

Leukemia

BTCRC-HEM17-092

Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092 Read More

BTCRC-AML18-342

Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia. Big Ten Cancer Research Consortium BTCRC-AML18-342

For full description, see clinicaltrials.gov, study #NCT04128020

CLL03-59

A Phase II Study of Ontak in Patients with Previously Treated Chronic Lymphocytic Leukemia

HOG-06

A Randomized Phase III Study of Low-Dose Cytosine Arabinoside vs Supportive Care in the Treatment of Preleukemia

Liver and Bile Duct

HCRN GI16-263

A phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma with pembrolizumab and Sylatron (peginterferon alfa-2b) HCRN GI16-263 Read More

BTCRC-GI13-002

An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002 Read More

GI06-101

Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101 Read More

Lung

HCRN LUN17-302

A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. HCRN: LUN17-302 Read More

HCRN LUN17-126

Randomized phase II study of durvalumab or durvalumab plus chemotherapy in Kras mutation positive and PD-L1 high (>/= 50%) NSCLC patients

For full description, see clinicaltrials.gov, study #NCT04470674

HCRN LUN15-233

Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous, Non-squamous or Not Otherwise Specified NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Read More

BTCRC-LUN15-029

A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029 Read More

HCRN LUN13-175

A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC): HCRN LUN13-175 Read More

LUN08-129

Phase II Study of Concurrent Pemetrexed and Radiation for Stage III Non-Small Cell Lung Cancer Read More

LUN07-130

A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies Read More

LUN06-116

Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Read More

LUN06-113

A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113 Read More

LUN06-107

A Phase II Trial of Concurrent Cisplatin/ Etoposide/ Radiotherapy Followed by Consolidation Sorafenib in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC) Read More

LUN05-99

Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study Read More

LUN04-79

A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79 Read More

LUN04-78

Pemetrexed (Alimta) in Patients with Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer Read More

LUN04-77

A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer Read More

LUN02-50

A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Read More

LUN02-29

A Phase II Trial of ZD1839 (IRESSA®) in Both Patients with Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers Read More

LUN01-25

Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination with Carboplatin-Paclitaxel in Patients with Chemo-therapy Naïve Advanced Non Small Cell Lung Cancer Read More

LUN01-24

A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24 Read More

LUN01-15

A Phase III Randomized Study of Taxotere 75/mg/M2 vs. ALIMTA for Second-line Chemo for Non-Small Cell Lung Cancer Read More

LUN00-12

A Randomized, Phase III Trial Comparing CPT-11/ Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive Small-Cell Lung Cancer Read More

LUN98-1

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Read More

LUN97-1

A Phase II Study of Taxol + Carboplatin + Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Read More

LUN96-2

A Phase II Study of Carboplatin plus Gemcitabine in Metastatic Non-Small Cell Lung Cancer Read More

LUN96-1

A Phase II Study of Paclitaxel (3-Hour Infusion and Bolus Doxorubicin in Recurrent or Refractory Small Cell Lung Cancer Read More

LUN95-1

A Phase III Study of Gemcitabine +Cisplatin vs Cisplatin Alone in Patients with Metastatic Non-Small Cell Lung Cancer Read More

LUN93-4

A Phase II Study of Gemcitabine + Cisplatin in Non-Small Cell Lung Cancer Read More

LUN93-3

A Phase II Study of VP-16 plus Ifosfamide plus Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer

LUN93-2

A Phase III Trial of Maintenance Daily Oral VP-16 vs no Further Therapy Following Induction Chemotherapy with VP-16 plus Ifosfamide plus Cisplatin (VIP) in Extensive Small Cell Lung Cancer Read More

LUN91-2

A Phase II Trial of CODE + G-CSF in Advanced NSCL Read More

LUN91-1

A Randomized Phase III Study of Definitive Radiation Therapy with or without Hydroxyurea in Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer Read More

LUN90-1

Phase II Trial of Carboplatin plus Interferon Alpha-2a in Advanced Non-Small Cell Lung Cancer Read More

LUN89-1

Phase II Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) as Combination Chemotherapy for Previously Treated Small Cell Lung Cancer

LUN88-6

Phase II Trial of Daily Oral Etoposide in Advanced Non-Small Cell Lung Cancer Read More

LUN88-4

Phase II Trial of Daily Oral Etoposide in Refractory Small Cell Lung Cancer

LUN88-3

Phase III Study of VP-16 + Cisplatin Alone (VP) + Ifosfamide (VIP) for Previously Untreated Extensive Small Cell Lung Cancer

LUN87-1

A Phase II Trial of VP-16, Ifosfamide and Cisplatin (VIP) Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer Read More

LUN86-1

A Randomized Phase III Study Of Definitive Radiation Therapy With/Without Cisplatinum in Previously Untreated Inoperable Non-Metastatic Non-Small Cell Lung Cancer Read More

HOG-14

Phase II Study of Vinblastine VP-16 (Etoposide), and Cisplatin (VEP) for Patients with Extensive Non-Small Cell Lung Cancer

HOG-12

A Phase II Trial of VP-16 and Split-Dose Cisplatin in Extensive Small Cell Lung Cancer

HOG-11

Phase III Study of Split Dose Cisplatinum Plus VP-16 in the Treatment of Locally Recurrent or Metastatic Non-Small Cell Lung Cancer

HOG-03

A Randomized Phase III Study of Variable Length of Treatment on Survival and Duration of Remission in Small Cell Lung Cancer

Lymphoma

BTCRC-HEM15-028

Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028 Read More

LYM08-134

Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma Read More

LYM03-64

A Phase II Study of Rituximab and Gemcitabine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Read More

NHL01-27

Phase I/II Study of CHOP plus Ontak, an Interleukin-2 Fusion Toxin for Patients with Peripheral T-cell Non-Hodgkin’s Lymphomas

NHL00-1

A Phase II Study of Single Agent Gemcitabine In Relapsed or Refractory Follicular or Small Lymphocytic Non-Hodgkin’s Lymphoma Read More

NHL92-1

Phase II Trial of Vincristine, Prednisone, Etoposide and Mitoxantrone in Elderly Patients with Aggressive Histology in Non-Hodgkin’s Lymphoma

NHL88-1

Phase II Trial of Carboplatin in Low-Grade Non-Hodgkin’s Lymphoma

HOG-08

Phase III Study of Treatment for Aggressive Non-Hodgkin’s Lymphoma – MACOP-B vs CHop

Melanoma

HCRN MEL16-261

MMP-01: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody With High Dose IL-2 in Metastatic Melanoma Read More

MEL91-1

A Phase III Study Comparing Cisplatin, Dacarbazine, Carmustine and Tamoxifen vs Dacarbazine Alone in Patients with Advanced Melanoma Read More

MEL90-1

Phase II Trial of Carboplatin plus Interferon Alpha-2a in Metastatic Melanoma

MEL89-1

Phase II Study of Daily Oral VP-16 in Previously Untreated Melanoma Read More

HOG-10

Phase II Study of Cimetidine in Patients with Metastatic Malignant Melanoma

Mutiple Myeloma

MM08-141

A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141

For full description, see www.clinicaltrials.gov.

MM02-35

A Phase II Study of Bisphosphonate: Zoledronic Acid (Zometa) in the Management of Asymptomatic/Early Stage Multiple Myeloma

MM01-21

A Phase II Study of Daily Thalidomide, Oral Cytoxan and Prednisone for Relapsed or Refractory Multiple Myeloma Read More

MM91-1

A Phase I/II Study of Carboplatin plus Interferon Alpha-2b in Untreated Multiple Myeloma

Myelodysplastic Syndromes

MDS04-85

A Phase II Randomized Trial with a Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients with Low-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts) Read More

MDS98-1

A Phase II Trial of Topotecan in Patients With Myelodysplastic Syndrome Read More

Neuroendocrine Tumors

BTCRC-GI19-400

Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400

Read More

Ovarian

GYN10-149

A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 Read More

GYN06-111

A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis Read More

GYN06-106

A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer Read More

GYN03-62

Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62 Read More

GYN98-1

A Phase II Trial of Ifosfamide and Oral Etoposide For Refractory Ovarian Cancer Read More

Pancreatic

GI00-11

A Phase II Study of Gemcitabine in Combination with Radiation Therapy in Patients with Localized Unresectable Pancreatic Cancer Read More

GI99-1

A Phase II Study of Gemcitabine and Docetaxel in Combination for Advanced Pancreatic Cancer Read More

GI98-1

Phase I/II Study of Gemcitabine and Docetaxel in Combination for Unresectable or Metastatic Pancreatic Cancer – GI98-1 Read More

GI91-1

Phase I/II Study of Weekly Oral MTX + AZT in the Treatment of Metastatic Adenocarcinoma of the Pancreas and Hepatoma – GI91-1 Read More

GI89-2

Phase II Study of 5-FU and Leucovorin + Radiation in Pancreatic Cancer Read More

Prostate

GU14-202

Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer with Enzalutamide and the Poly (ADP-Ribose) Polymerase [PARP] Inhibitor Niraparib. Read More

GU13-170

Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170. Read More

GU12-159

The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159 Read More

GU07-124

A Phase II Study of Neoadjuvant Dasatinib plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer Read More

GU03-67

A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67 Read More

GU02-41

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy Read More

GU00-9

A Multicenter Randomized Phase II Study of Docetaxel plus Vinorelbine and Doxetacel plus Estramustine in Combination for Hormone Refractory Prostate Cancer Read More

GU98-1

Phase II Study of Vinorelbine plus Estramustine in Metastatic Hormone-Refractory Prostate Cancer Read More

GU97-1

Phase II Study of Diethylstilbestrol in Metastatic Prostate Cancer

GU93-1

A Phase III Study of Vinblastine vs Vinblastine plus Estramustine for Metastatic Hormone Refractory Prostatic Cancer Read More

GU90-2

Phase II Study of Flutamide Plus Interferon Alpha-2b in Metastatic Hormone Resistant Prostate Cancer

HOG-02

Phase III Randomized Comparison of Cyclophosphamide vs Cyclophosphamide + Adriamycin + Methotrexate for Stage IV Hormone Resistant Prostatic Cancer

Quality of Life

QL12-153

Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153 Read More

QL05-37

Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen Read More

QL03-70

Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting Read More

QL02-45

Increasing Screening in Families with Colorectal Cancer

QL02-44

Enhancing Connections: Helping the Mother with Breast Cancer Support Her Child

QL01-26

A Phase II Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy Read More

QL01-22

Predictors of Quality of Life After Treatment for Colorectal Cancer

QL00-4

A Phase I Trial of Olanzapine (Zyprexa) For the Prevention of Delayed Emesis In Cancer Patients Receiving Chemotherapy Read More

QL97-1

Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Randomized, Double-Blind, Placebo-Controlled Trial Read More

HOG89-1

Carboplatin in Hypercalcemia

Rectal

GI03-53

A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer – GI03-53 Read More

Sample Collection

BNK09-138

A Biological Sample Collection Protocol of Patients with and without Metastatic Solid Organ Malignancies Read More

Sarcoma

SAR90-1

Phase II Trial of Daily Oral Etoposide in Advanced Sarcoma

Urothelial Carcinoma